Diabetic eye disease refers to a group of eye problems that people with diabetes may face as a complication of diabetes. All can cause severe vision loss or even blindness. Diabetic eye disease may include, diabetic retinopathy — damage to the blood vessels in the retina, Cataract—clouding of the eye's lens, glaucoma—increase in fluid pressure inside the eye that leads to optic nerve damage and loss of vision. A person with diabetes is nearly twice as likely to get glaucoma as other adults.
Cardiovascular complications and hypoglycemia (low blood sugar) were common nonfatal complications in adults 60 years of age and older with diabetes, according to a study published by JAMA Internal Medicine, a JAMA Network publication.
Blurred images that are unidentifiable as still pictures become understandable once the images are set in motion. That's because of a phenomenon called "optic flow"—which may be especially relevant as a source of visual information in people with low vision, reports a study 'With an Eye to Low Vision: Optic Flow Enables Perception Despite Image Blur' in the October issue of Optometry and Vision Science official journal of the American Academy of Optometry.
Researchers at the Eugene and Marilyn Glick Eye Institute and the Indiana Center for Vascular Biology at Indiana University School of Medicine are on the cusp of perfecting stem cell treatments that would halt - and potentially reverse - vision loss caused by diabetic retinopathy.
Weill Cornell Medical College's ophthalmology services for diabetic patients received a boost last month, courtesy of a grant from the New York City Council secured by Councilwoman Jessica Lappin.
Massachusetts Eye and Ear and the Joslin Diabetes Center announced today that they have reached agreement to form a clinical and research alliance, aimed toward providing coordinated high quality care to eye patients throughout greater Boston, especially those with or at-risk for diabetes-related eye disease.
Genentech, a member of the Roche Group, today announced that Lucentis (ranibizumab injection) was approved by the U.S. Food & Drug Administration (FDA) for treatment of diabetic macular edema (DME), an eye condition in people with diabetes that causes blurred vision, severe vision loss and sometimes blindness
The U.S. Food and Drug Administration today approved Lucentis (ranibizumab injection) for the treatment of diabetic macular edema (DME), a sight-threatening eye disease that occurs in people with diabetes.
Researchers at Joslin Diabetes Center, supported by JDRF, have completed a study of 158 people who have lived with type 1 diabetes (T1D) for 50 years or more with eye examinations at Joslin over many decades of follow-up, and have concluded that a high proportion of this unique group of patients developed little to no diabetic eye disease over time.
Aerpio Therapeutics, a clinical‐stage biopharmaceutical company focused on advancing innovative therapies for the treatment of diabetic eye disease and inflammatory bowel disease, today announced positive data from its Phase 1 trial of AKB-9778 for the treatment of diabetic macular edema.
Presently Indigenous Australians suffer six times the blindness of mainstream Australians and 94 percent of vision loss in Indigenous Australians is unnecessary, preventable or treatable.
KalVista Pharmaceuticals and JDRF have formed a research partnership focused on a novel approach being developed by KalVista to preserve vision and slow the progression of diabetic eye disease.
JDRF-funded researchers have begun enrolling adult patients with type 1 diabetes (T1D) in the REMOVAL study, to test whether metformin-a drug commonly used to treat type 2 diabetes-could help prevent or reduce the risk of cardiovascular complications in people with T1D.
Akebia Therapeutics, Inc., a small molecule discovery and development company focused on anemia and vascular disorders, today announced that it has dosed the first subjects in a first-in-man Phase 1 study of AKB-9778, a first-in-class human protein tyrosine phosphatase beta (HPTPβ) inhibitor in development for diabetic macular edema (DME) and diabetic retinopathy (DR).
According to the American Diabetes Association (ADA), recent estimates project that as many as one in three American adults will have diabetes in 2050. The ADA has named the month of November American Diabetes Month to help educate people on simple ways they can help manage, control and even prevent early signs of the disease - such as high blood pressure.
iCo Therapeutics Inc. today announced that the company has entered into a research collaboration agreement with JDRF, the worldwide leader for research to cure, treat, and prevent type 1 diabetes (T1D), to support the previously announced Phase 2 investigator sponsored clinical trial investigating iCo-007 in Diabetic Macular Edema.
Genentech, a member of the Roche Group, today announced 24-month results from the two pivotal Phase III trials (RISE and RIDE) assessing the efficacy and safety of Lucentis (ranibizumab injection) in people with diabetic macular edema (DME).
Genentech, a member of the Roche Group, announced today that the second of two Phase III trials evaluating Lucentis in patients with diabetic macular edema met its primary endpoint.
Genentech, a member of the Roche Group, today announced that two-year results from a pivotal Phase III trial showed patients with diabetic macular edema who received Lucentis experienced rapid and sustained improvement in vision compared to those who received a placebo injection.
Genentech, Inc., a member of the Roche Group, announced today that one of two Phase III studies evaluating monthly Lucentis® (ranibizumab injection) in patients with diabetic macular edema (DME), met its primary endpoint. DME is a serious complication of diabetes that affects up to 10 percent of people with the disease and can lead to blurred vision, severe vision loss and blindness.
Future Medicine Ltd has today announced the launch of Diabetes Management – a new bimonthly title presenting findings, analyses and commentaries on the battle with Type 1 and Type 2 diabetes. Diabetes Management is published by Future Medicine Ltd (UK, London) renowned for its collection of journals providing healthcare practitioners and research professionals with a unique source of objective, cutting-edge information on exciting trends emerging in light of advances in medicine, healthcare and clinical practice.